Carratt, Sarah A. http://orcid.org/0000-0003-2493-6789
Kong, Garth L. http://orcid.org/0000-0001-5262-5406
Coblentz, Cody
Schonrock, Zachary
Maloney, Lauren
Weeder, Ben http://orcid.org/0000-0002-4128-5861
Yashar, Will http://orcid.org/0000-0002-8850-9850
Callahan, Rowan
Blaylock, Hunter http://orcid.org/0000-0002-0606-502X
Coleman, Colin
Coleman, Dan
Braun, Theodore P. http://orcid.org/0000-0002-6248-2143
Maxson, Julia E. http://orcid.org/0000-0002-3871-7221
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI F32CA239422, 1 K08 CA245224, NCI R01 CA247943)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
American Cancer Society (RSG-19-184-01-LIB)
Leukemia and Lymphoma Society
Article History
Received: 19 December 2022
Revised: 20 February 2023
Accepted: 24 February 2023
First Online: 9 March 2023
Competing interests
: JEM discloses a collaboration with Ionis pharmaceuticals, research funding from Gilead Sciences, Kura Oncology and Blueprint Medicines. WY is a former employee of Abreos Biosciences, Inc. and was compensated in part with common stock options. Pursuant to the merger and reorganization agreement between Abreos Biosciences, Inc. and Fimafeng, Inc., WY surrendered all of his common stock options in March 2021. The other authors do not have conflicts of interest, financial or otherwise.